Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRALS: Phase 2 Study of VHB937 in Amyotrophic Lateral Sclerosis
jRCT2061240119Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing VHB937 with Placebo (2 arms). Primary endpoint: Composite of PAV-free survival and change in ALSFRS-R. Started Mar 2025; status: completed.
02
Drugs
VHB937
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2061240119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240119.